Arena Pharmaceuticals - ARNA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $95.60
  • Forecasted Upside: -4.39 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$99.99
+0 (0.00%)
Get New Arena Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARNA

Analyst Price Target is $95.60
▼ -4.39% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Arena Pharmaceuticals in the last 3 months. The average price target is $95.60, with a high forecast of $105.00 and a low forecast of $71.00. The average price target represents a -4.39% upside from the last price of $99.99.

This chart shows the closing price for ARNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in Arena Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
2/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 0 sell ratings
2/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
5/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
7/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2022HC WainwrightDowngradeBuy ➝ Neutral$120.00 ➝ $100.00Low
12/20/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$93.00 ➝ $100.00Low
12/14/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$112.00 ➝ $100.00Medium
12/14/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal WeightMedium
12/14/2021CitigroupDowngradeBuy ➝ Neutral$101.00 ➝ $100.00Medium
12/14/2021JMP SecuritiesDowngradeMarket Outperform ➝ Market PerformMedium
12/14/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$76.00 ➝ $100.00Medium
12/14/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral$98.00 ➝ $100.00Medium
12/14/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$100.00Medium
12/13/2021Needham & Company LLCReiterated RatingBuy ➝ HoldHigh
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$71.00High
12/1/2021SVB LeerinkReiterated RatingBuyHigh
10/14/2021SVB LeerinkReiterated RatingBuyMedium
9/30/2021HC WainwrightReiterated RatingBuy$120.00Medium
9/28/2021Credit Suisse GroupReiterated RatingBuy$98.00Medium
9/28/2021Needham & Company LLCReiterated RatingBuy$80.00Medium
9/28/2021JMP SecuritiesReiterated RatingBuy$105.00Medium
9/24/2021HC WainwrightReiterated RatingBuy$120.00Low
9/22/2021Needham & Company LLCReiterated RatingBuy$80.00Low
9/22/2021JMP SecuritiesReiterated RatingBuy$105.00Low
8/10/2021Cantor FitzgeraldLower TargetOverweight$100.00 ➝ $93.00High
8/6/2021Credit Suisse GroupLower TargetOutperform$102.00 ➝ $98.00High
7/28/2021HC WainwrightReiterated RatingBuyHigh
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$90.00Medium
5/7/2021SVB LeerinkBoost TargetOutperform$90.00 ➝ $112.00High
4/27/2021CitigroupInitiated CoverageBuy$104.00Low
4/15/2021Needham & Company LLCReiterated RatingBuyLow
4/13/2021Credit Suisse GroupBoost TargetOutperform$87.00 ➝ $102.00Medium
3/26/2021HC WainwrightBoost TargetBuy$90.00 ➝ $120.00Low
3/3/2021Cantor FitzgeraldLower TargetPositive ➝ Overweight$106.00 ➝ $100.00High
3/3/2021JonestradingLower TargetAverage ➝ Buy$101.00 ➝ $94.00High
2/25/2021SVB LeerinkLower TargetOutperform$92.00 ➝ $90.00Low
1/28/2021JonestradingInitiated CoverageBuyHigh
11/19/2020Smith Barney CitigroupInitiated CoverageOutperform$100.00Medium
11/10/2020GuggenheimLower TargetBuy$115.00 ➝ $105.00High
11/10/2020Royal Bank of CanadaLower TargetPositive ➝ Outperform$80.00 ➝ $76.00High
11/10/2020SVB LeerinkBoost TargetOutperform$91.00 ➝ $92.00High
11/2/2020JPMorgan Chase & Co.Boost Target$71.00 ➝ $90.00Medium
10/13/2020Cantor FitzgeraldBoost Target$88.00 ➝ $110.00Low
9/30/2020Bank of AmericaBoost TargetBuy$75.00 ➝ $85.00Medium
9/18/2020CitigroupBoost TargetBuy$83.00 ➝ $120.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/17/2020GuggenheimBoost TargetBuy$95.00 ➝ $115.00Low
8/6/2020HC WainwrightReiterated RatingBuy$90.00High
8/6/2020Wells Fargo & CompanyBoost TargetOverweight$60.00 ➝ $78.00Low
8/6/2020SVB LeerinkBoost TargetOutperform$73.00 ➝ $91.00Low
8/6/2020Needham & Company LLCReiterated RatingBuy$70.00Low
7/27/2020CitigroupBoost TargetBuy$65.00 ➝ $83.00Medium
6/29/2020HC WainwrightInitiated CoverageBuy$90.00High
6/2/2020Credit Suisse GroupBoost TargetPositive ➝ Outperform$77.00 ➝ $87.00Medium
5/18/2020Jefferies Financial GroupInitiated CoverageBuy$62.00High
5/8/2020Cantor FitzgeraldReiterated RatingBuy$56.00 ➝ $68.00Low
4/14/2020Needham & Company LLCReiterated RatingBuy$70.00High
3/31/2020GuggenheimInitiated CoverageBuy$95.00Low
3/26/2020Bank of AmericaUpgradeNeutral ➝ Buy$47.00 ➝ $56.00High
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$62.00 ➝ $56.00High
1/31/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$58.00High
1/27/2020Royal Bank of CanadaReiterated RatingBuy$83.00Medium
11/14/2019Wood & CompanyReiterated RatingSellMedium
11/13/2019Bank of AmericaInitiated CoverageNeutral$51.00Low
8/11/2019Royal Bank of CanadaReiterated RatingBuy$79.00High
5/8/2019Cantor FitzgeraldReiterated RatingBuyHigh
4/3/2019Credit Suisse GroupBoost TargetOutperform ➝ Outperform$63.00 ➝ $77.00High
2/26/2019Cantor FitzgeraldReiterated RatingBuy$62.00High
1/28/2019Cantor FitzgeraldReiterated RatingBuy$62.00Low
12/13/2018Berenberg BankInitiated CoverageBuy ➝ Buy$55.00Low
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/19/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$56.00 ➝ $61.00Low
11/16/2018Royal Bank of CanadaBoost TargetOutperform$70.00Low
11/15/2018Needham & Company LLCSet TargetBuy$60.00High
11/15/2018Cantor FitzgeraldSet TargetBuy$65.00Low
11/7/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
9/24/2018Cantor FitzgeraldSet TargetBuy$65.00High
8/7/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$58.00 ➝ $56.00High
5/31/2018Royal Bank of CanadaInitiated CoverageOutperform$65.00Medium
3/21/2018CitigroupReiterated RatingPositive ➝ Buy$62.00High
3/20/2018JMP SecuritiesBoost TargetMkt Outperform ➝ Outperform$63.00 ➝ $79.00High
3/20/2018Wells Fargo & CompanyLower TargetPositive ➝ Outperform$53.00 ➝ $60.00High
3/20/2018Needham & Company LLCUpgradeHold ➝ Buy$30.89 ➝ $60.00High
3/14/2018Needham & Company LLCReiterated RatingHoldHigh
2/27/2018CitigroupBoost TargetBuy ➝ Buy$37.00 ➝ $55.00High
2/20/2018JMP SecuritiesBoost TargetOutperform$36.00 ➝ $63.00Low
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$44.00Low
1/17/2018SVB LeerinkReiterated RatingOutperform ➝ Positive$53.00 ➝ $56.00Low
1/17/2018Cantor FitzgeraldReiterated RatingBuy$45.00Low
1/3/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
9/25/2017Cantor FitzgeraldReiterated RatingBuy$37.00High
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/21/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/20/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $99.99
Low: $99.99
High: $99.99

50 Day Range

MA: $97.65
Low: $93.13
High: $99.99

52 Week Range

Now: $99.99
Low: $45.50
High: $100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Arena Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Arena Pharmaceuticals in the last year: Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Needham & Company LLC, Royal Bank of Canada, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for ARNA.

What is the current price target for Arena Pharmaceuticals?

10 Wall Street analysts have set twelve-month price targets for Arena Pharmaceuticals in the last year. Their average twelve-month price target is $95.60, suggesting a possible downside of 4.4%. JMP Securities has the highest price target set, predicting ARNA will reach $105.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $71.00 for Arena Pharmaceuticals in the next year.
View the latest price targets for ARNA.

What is the current consensus analyst rating for Arena Pharmaceuticals?

Arena Pharmaceuticals currently has 10 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ARNA, but not buy more shares or sell existing shares.
View the latest ratings for ARNA.

What other companies compete with Arena Pharmaceuticals?

How do I contact Arena Pharmaceuticals' investor relations team?

Arena Pharmaceuticals' physical mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company's listed phone number is (858) 453-7200 and its investor relations email address is [email protected] The official website for Arena Pharmaceuticals is www.arenapharm.com. Learn More about contacing Arena Pharmaceuticals investor relations.